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Summary
. The median height z-score for paediatric patients on
dialysis in 2015 was −1.8 and for those with a func-
tioning transplant −1.2. Children transplanted
before the age of 12 years improved their height
z-score over the subsequent ﬁve years, whereas
those older than 12 years maintained their height
z-score, with all transplanted patients having a
similar median height z-score after ﬁve years of
starting renal replacement therapy (RRT).
. The median weight z-score for children on dialysis
in 2015 was−1.1, whereas children with a function-
ing transplant had a near normal weight for age and
sex with a median z-score of −0.2.
. Of those with data, 75% of the prevalent paediatric
RRT population in 2015 had one or more ‘tradi-
tional’ risk factors for cardiovascular disease, with
7% having all three risk factors present.
. For the 12 centres reporting quarterly laboratory
data, the median creatinine in transplant patients
in 2015 was 79 mmol/L; on average, dialysis patients
in 2015 had normal anaemia and acidosis param-
eters and evidence of secondary hyperparathyroid-
ism, with a median parathyroid hormone (PTH)
of 21 pmol/L.
. For transplant patients, 82% achieved the systolic
blood pressure (SBP) standard and 93% achieved
the haemoglobin standard in 2015.
. For haemodialysis patients, 63% achieved the SBP
standard, 73% achieved the haemoglobin standard,
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76% achieved the calcium standard, 48% achieved
the phosphate standard and 45% achieved the
PTH standard in 2015.
. For peritoneal dialysis patients, 63% achieved the
SBP standard, 75% achieved the haemoglobin stan-
dard, 70% achieved the calcium standard, 52%
achieved the phosphate standard and 32% achieved
the PTH standard in 2015.
Introduction
This chapter focuses on the following variables for the
prevalent paediatric dialysis and transplantation cohort
on 31st December 2015:
1. The completeness of data returns to the UK Renal
Registry (UKRR)
2. Anthropometric characteristics and growth
3. Cardiovascular risk factors (CVRFs)
4. Laboratory and clinical indices, including anaemia
control and biochemical ﬁndings.
Analyses of prevalent paediatric patients aged ,18
years receiving renal replacement therapy (RRT) for the
year 2015 and for the period 2003–2015 inclusive, are
reported. A single dataset was collected for each patient
per year during this time period. Where possible, analyses
of incident cohorts were conducted, with centre-speciﬁc
data for each paediatric nephrology centre in the UK
also being provided.
Methods
Processes for data collection for the paediatric UKRR are
described in chapter 4. The data presented in this chapter relate
to the annual census date of 31st December 2015.
Standards and standardisation
Standards are in bold text and are from the Renal Association’s
(2002) ‘Treatment of adults and children with renal failure: stan-
dards and audit measures (third edition)’ [1], unless otherwise
stated.
Where the value of clinical parameters in childhood varies with
age, sex and size, data are presented as z-scores.
Anthropometry
‘Measures of supine length or standing height and weight
should be monitored at each clinic visit. All measurements
should be plotted on European reference growth charts for
healthy children.’
The reference range for height (Ht), weight (Wt) and body
mass index (BMI) in childhood varies with gender and age.
BMI was calculated using the formula BMI =Wt (kg)/
Ht2 (m). Ht and Wt were adjusted for age. To account for dis-
crepancies in linear growth secondary to renal disease, BMI was
expressed according to Ht-age, rather than chronological age.
The International Obesity Taskforce deﬁnition [2] was used
to deﬁne overweight and obesity; z-scores were calculated
based on the British 1990 reference data for Ht and Wt [3].
Blood pressure
‘Blood pressure varies throughout childhood and should be
maintained within two standard deviations of the mean for
normal children of the same height and sex. The systolic
blood pressure during peritoneal dialysis or after haemodialy-
sis should be maintained at <90th centile for age, gender and
height.’
‘In paediatric renal transplant patients, the systolic blood
pressure should be maintained at <90th percentile for age,
gender and height.’
The analyses of systolic blood pressure (SBP) in this report
present the achievement of SBPs at or below the 90th percen-
tile. Guidance for blood pressure in paediatric renal transplant
patients was based on 2011 British Association for Paediatric
Nephrology recommendations [4].
The reference range for SBP varies with gender, age and Ht.
The data are therefore presented as z-scores based on data from
the fourth report of the National High Blood Pressure Educa-
tion Programme working group in the United States [5].
Cholesterol
The National Heart Lung and Blood Institute recommends
screening for dyslipidaemias in children with chronic kidney
disease (CKD)/established renal failure (ERF)/post renal trans-
plant (deemed high risk) between the ages of two and 17 years,
and deﬁnes high total cholesterol as≥5.2 mmol/L [6]. This cut-
off has been adopted for this report.
Haemoglobin and ferritin
Guidance on the management of anaemia in adults and
children with CKD was updated and published by the National
Institute for Health and Care Excellence in February 2011
(clinical guideline 114) [7]. Subsequent guidance was issued
during the 2015 data collection period and uses the same
haemoglobin (Hb) parameters as previously but recommends
newer methods of assessing iron stores over ferritin.
‘Typically maintain the aspirational Hb range between
100 and 120 g/L for young people and children aged 2 years
and older, and between 95 and 115 g/L for children younger
than 2 years of age, reﬂecting the lower normal range in
that age group.’
Hb and ferritin were analysed using age-related laboratory
reference ranges as in table 9.1.
Calcium, phosphate and parathyroid hormone (PTH)
‘Serum phosphate and calcium should be kept within the
normal range. PTH levels should be maintained within
twice the upper limit of the normal range but, contrary to
adult standards, may be kept within the normal range if
growth is normal.’
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Calcium, phosphate and PTH were analysed using age-
related laboratory reference ranges as in table 9.1. Individual
variable data analysis has been performed per centre and
nationally. It should be noted that ‘normal’ growth is difﬁcult
to determine in the setting of paediatric RRT.
Bicarbonate
‘Serum bicarbonate concentrations should be between 20
and 26 mmol/L.’
Bicarbonate reference ranges vary by centre and are
reported as within or outside the reference range as given in
table 9.1.
Cardiovascular risk factors
A cross-sectional evaluation of the prevalence of traditional risk
factors for cardiovascular disease, including hypertension, over-
weight/obesity and hypercholesterolaemia in children with ERF
is presented. In this analysis, the prevalence of one or more
CVRFs in children with ERF in the UK is shown. Evidence for
the use of total cholesterol and the relationship of childhood
CVRFs with adult CVRFs is available from The National Heart
Lung and Blood Institute [6].
Statistical analyses
Annual and quarterly clinical and laboratory data have been
analysed separately, with annual data being used unless stated
otherwise. Data were analysed to calculate summary statistics
(maximum, minimum, mean and median values in addition to
standard deviation and quartile ranges). Where applicable, the per-
centage achieving the audit standard was also calculated. If a patient
had missing data, they were excluded from the relevant analyses.
Estimated glomerular ﬁltration rate (eGFR) was calculated
using the Schwartz formula [8], using centre-speciﬁc individual
correction factors submitted to the UKRR.
Longitudinal analyses of attainment of standards were also per-
formed. These were based on a single data point per ERF patient
per year collected as described previously. Caution should be exer-
cised in the interpretation of analyses based on data items from a
single annual measurement per patient. This is due to changing
audit standards over time and variable data returns for previous
years. Furthermore, for biochemical variables there are not only
differences between assays used at different centres to consider,
but also differences in the timing of the result between modalities.
All analyses were performed using SAS 9.3.
Results
Data completeness
Annual data
Tables 9.2 and 9.3 show the completeness of annual
data returns for transplant and dialysis patients for 2015.
Overall, completeness was excellent for key variables
in both groups, with the larger group of transplant
patients having better completeness for Ht, BMI, and
SBP and the smaller group of dialysis patients having
better completeness for PTH. Ferritin completeness was
relatively low in transplant patients, which may reﬂect
satisfactory graft function and anaemia control, or use
of alternative methods of assessing iron stores. Reporting
of therapy for anaemia remained patchy and a cholesterol
value was reported to the paediatric UKRR for only half
of the patients.
Quarterly data
Twelve centres supplied quarterly 2015 data to the
UKRR. Completeness of these data is shown for trans-
plant patients in table 9.4 and dialysis patients in
table 9.5. For transplant patients, ferritin and PTH were
included in quarterly returns, but were not widely used;
the overall quarterly completeness for ferritin in trans-
plant patients was 40% and for PTH was 59%.
Table 9.1. Summary of relevant biochemical clinical audit measures
Parameter
Age (years)
,1 1–5 6–12 .12
Hb (g/L), NICE guideline CG 114 Maintain 95–115
if aged ,2 years
Maintain 100–120
if aged .2 years
100–120 100–120
Ferritin (mg/L) 200–500 200–500 200–500 200–500
Corrected calcium (mmol/L) 2.24–2.74 2.19–2.69 2.19–2.69 2.15–2.55
Phosphate (mmol/L) 1.10–1.95 1.05–1.75 1.05–1.75 1.05–1.75
PTH (individual centre) Within twice the normal range
Levels may be maintained within normal range if growing appropriately
Bicarbonate (mmol/L) Reported as either within or outside centre reference range
Hb – haemoglobin; NICE – National Institute for Health and Care Excellence; PTH – parathyroid hormone
Paediatric biochemistry Nephron 2017;137(suppl1):235–250 237
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Growth
Height
Figures 9.1 and 9.2 show that children receiving RRT
were short for their age and sex and that those on dialysis
were signiﬁcantly shorter than those with renal trans-
plants. The overall median z-score (shown by the dotted
line) was −1.2 in the transplanted group and −1.8 in the
dialysis group (p , 0.0001). Evelina was excluded from
ﬁgure 9.2 because few Ht data for dialysis patients
were reported. Figure 9.3 demonstrates that by the
Table 9.2. Percentage data completeness for transplant patients ,18 years old by centre for each variable and total number of
patients per centre on 31st December 2015
Transplant patients % completeness
Centre N Ht Wt BMI SBP Hb Creat Ferr ESA
IV
iron Chol Bicarb PTH Ca Phos
Bham_P∗ 85 100.0 100.0 100.0 100.0 98.8 98.8 51.9 0.0 0.0 1.2 98.8 96.4 98.8 98.8
Blfst_P∗ 18 100.0 100.0 100.0 100.0 100.0 100.0 94.4 100.0 100.0 88.2 100.0 88.9 100.0 100.0
Brstl_P∗ 39 92.3 97.4 92.3 84.6 100.0 100.0 52.6 100.0 89.7 68.4 97.4 65.8 100.0 100.0
Cardf_P 23 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 95.7 100.0 100.0 100.0 100.0
Glasg_P∗ 42 100.0 100.0 100.0 100.0 100.0 100.0 67.5 100.0 100.0 43.9 100.0 100.0 100.0 100.0
L Eve_P∗ 82 97.6 98.8 97.6 98.8 98.8 93.9 95.1 100.0 100.0 81.5 93.9 93.9 93.9 93.9
L GOSH_P∗ 150 100.0 100.0 100.0 99.3 100.0 100.0 92.0 88.0 87.3 61.9 98.7 98.0 100.0 100.0
Leeds_P∗ 68 89.7 100.0 89.7 97.1 100.0 100.0 79.4 100.0 100.0 41.8 100.0 88.2 100.0 100.0
Livpl_P 43 93.0 93.0 93.0 93.0 93.0 93.0 73.8 90.7 93.0 72.1 93.0 7.1 93.0 93.0
Manch_P∗ 61 98.4 100.0 98.4 100.0 100.0 100.0 73.8 96.7 96.7 16.4 100.0 100.0 100.0 100.0
Newc_P∗ 27 100.0 100.0 100.0 100.0 100.0 100.0 92.6 100.0 100.0 88.0 100.0 88.9 100.0 100.0
Nottm_P∗ 69 86.6 88.1 86.6 82.4 92.5 92.7 82.8 92.7 1.5 84.1 92.7 75.8 92.7 92.7
Soton_P 25 96.0 100.0 96.0 88.0 100.0 100.0 88.0 96.0 96.0 64.0 100.0 100.0 100.0 100.0
UK 732 96.4 98.2 96.4 96.2 98.6 98.1 79.9 84.3 75.2 56.3 97.7 87.3 98.1 98.1
Ht – height; Wt – weight; BMI – body mass index; SBP – systolic blood pressure; Hb – haemoglobin; Creat – creatinine; Ferr – ferritin;
ESA – erythropoietin stimulating agent; IV – intravenous; Chol – cholesterol; Bicarb – bicarbonate; PTH – parathyroid hormone; Ca –
calcium; Phos – phosphate
∗Denotes centre undertaking paediatric kidney transplantation
Table 9.3. Percentage data completeness for dialysis patients ,18 years old by centre for each variable and total number of patients
per centre on 31st December 2015
Centre
Dialysis patients % completeness
N Ht Wt BMI SBP Hb Ferr ESA
IV
iron Chol Bicarb PTH Ca Phos
Bham_P 25 92.0 88.0 88.0 96.0 96.0 89.7 0.0 0.0 0.0 96.0 92.6 96.0 96.0
Blfst_P 7 87.5 100.0 87.5 100.0 100.0 100.0 100.0 100.0 62.5 100.0 100.0 100.0 100.0
Brstl_P 17 94.1 100.0 94.1 100.0 100.0 100.0 100.0 82.4 77.8 100.0 94.4 100.0 100.0
Cardf_P 8 100.0 100.0 100.0 87.5 100.0 100.0 100.0 100.0 62.5 100.0 100.0 100.0 100.0
Glasg_P 14 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 73.3 100.0 100.0 100.0 100.0
L Eve_P 18 11.1 27.8 11.1 27.8 88.9 100.0 100.0 100.0 63.2 94.4 94.4 94.4 94.4
L GOSH_P 29 93.1 100.0 93.1 100.0 100.0 86.7 86.2 86.2 62.5 100.0 100.0 100.0 100.0
Leeds_P 14 85.7 92.9 85.7 92.9 100.0 100.0 100.0 100.0 60.0 100.0 100.0 100.0 100.0
Livpl_P 13 69.2 84.6 69.2 84.6 84.6 78.6 92.3 76.9 30.8 61.5 85.7 92.3 92.3
Manch_P 30 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 55.6 100.0 100.0 100.0 100.0
Newc_P 9 88.9 88.9 88.9 88.9 100.0 100.0 100.0 100.0 90.9 100.0 100.0 100.0 100.0
Nottm_P 18 85.0 85.0 85.0 57.9 100.0 100.0 100.0 42.1 55.6 100.0 100.0 100.0 100.0
Soton_P 7 100.0 100.0 100.0 57.1 85.7 100.0 85.7 85.7 14.3 100.0 100.0 100.0 100.0
UK 209 84.9 89.1 84.4 85.7 97.2 95.5 85.2 77.6 53.8 96.7 97.2 98.6 98.6
Ht – height; Wt – weight; BMI – body mass index; SBP – systolic blood pressure; Hb – haemoglobin; Ferr – ferritin; ESA – erythropoietin
stimulating agent; IV – intravenous; Chol – cholesterol; Bicarb – bicarbonate; PTH – parathyroid hormone; Ca – calcium; Phos – phosphate
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Table 9.4. Percentage data completeness for transplant patients ,18 years old by centre reporting quarterly laboratory data and
total number of patients per centre on 31st December 2015
Centre
Transplant patients % completeness
N Creatinine Hb Calcium Phosphate Bicarbonate
Bham_P 85 91.8 93.1 90.9 91.2 90.3
Blfst_P 18 100.0 98.6 100.0 100.0 100.0
Brstl_P 39 96.1 92.8 91.4 91.4 86.8
Cardf_P 23 96.5 94.1 96.5 96.5 96.5
Glasg_P 42 100.0 99.4 99.4 99.4 100.0
L Eve_P 82 94.3 71.7 94.3 94.3 94.3
L GOSH_P 150 95.2 94.8 95.2 94.8 92.9
Leeds_P 68 94.4 94.0 94.0 93.6 92.8
Manch_P 61 100.0 99.5 100.0 100.0 100.0
Newc_P 27 88.0 84.0 88.0 88.0 84.0
Nottm_P 69 86.7 83.8 85.1 85.9 84.2
Soton_P 25 63.6 58.6 59.6 59.6 59.6
UK 689 93.2 89.6 92.4 92.4 91.2
Hb – haemoglobin
Table 9.5. Percentage data completeness for dialysis patients ,18 years old by centre reporting quarterly laboratory data and total
number of patients per centre on 31st December 2015
Centre
Dialysis patients % completeness
N Hb Ferritin Calcium Phosphate PTH Bicarbonate
Bham_P 25 91.0 73.0 92.0 92.0 83.0 91.0
Blfst_P 7 100.0 96.6 96.6 100.0 93.1 100.0
Brstl_P 17 100.0 84.8 100.0 100.0 97.0 100.0
Cardf_P 8 100.0 100.0 100.0 100.0 96.8 100.0
Glasg_P 14 100.0 96.4 98.2 98.2 92.7 100.0
L Eve_P 18 65.1 72.3 84.3 84.3 83.1 84.3
L GOSH_P 29 100.0 45.0 100.0 100.0 100.0 100.0
Leeds_P 14 96.7 88.5 95.1 95.1 93.4 96.7
Manch_P 13 96.0 95.2 96.0 95.2 96.0 96.0
Newc_P 9 97.3 100.0 100.0 97.3 100.0 97.3
Nottm_P 18 97.4 93.4 97.4 97.4 89.5 96.1
Soton_P 7 85.7 100.0 100.0 100.0 92.9 100.0
UK 179 94.0 82.0 96.2 96.1 93.0 96.1
Hb – haemoglobin; PTH – parathyroid hormone
H
ei
gh
t z
-s
co
re
–4.0
–3.0
–2.0
–1.0
0.0
1.0
2.0
3.0
4.0
Bh
am
_P
Br
st
l_
P
L 
G
O
SH
_P
G
la
sg
_P
N
ew
c_
P
L 
Ev
e_
P
Ca
rd
f_
P
Li
vp
l_
P
So
to
n_
P
Bl
fs
t_
P
N
ot
tm
_P
M
an
ch
_P
Le
ed
s_
P
U
K
N = 703 Upper quartile
 Median
 Lower quartile
Fig. 9.1. Median height z-scores for
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31st December 2015, centre speciﬁc and
national averages
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time of RRT start, children were already short for their
age and sex with an overall median z-score of −1.4,
with younger children aged two to eight years most
affected. Figure 9.4 shows that although transplanted
paediatric patients aged up to 12 years improved their
Ht z-score in the ﬁrst ﬁve years of starting RRT, those
older than 12 years started with a better Ht z-score
which was maintained. In contrast, all dialysis patients
had a worsening Ht z-score over time. Poor growth
was more pronounced in the oldest children, who
exhibited better growth at RRT start. Due to changes
in modality, groups are not strictly sequential in this
analysis and because most patients received a transplant,
there are small numbers of dialysis patients at ﬁve years
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Fig. 9.2. Median height z-scores for dialysis
patients ,18 years old on 31st December
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after starting RRT. Data for 16–18 year olds were
omitted owing to small group numbers.
The proportion of patients aged two to 18 years with a
Ht less than two standard deviations (SDs) in 2015 was
much higher for those on dialysis (43.4% for haemo-
dialysis (HD) and 34.4% for peritoneal dialysis (PD))
compared to those with a functioning transplant
(27.1%), excluding patients with syndromes and those
born prematurely where growth might be compromised..
Figure 9.5 shows large variation over the 13 years to 2015
in the use of growth hormone in those with a Ht less than
two SDs. The proportion of patients with a Ht less than
two SDs whose growth hormone status was not known
is high (changing from approximately 10% in 2010 to
50% in 2011) and this limits meaningful interpretation.
Average use of growth hormone for patients aged ,18
years with a Ht less than two SDs since 2003 was 18.1%
for dialysis patients and 7.4% for transplant patients.
Weight
Figures 9.6 and 9.7 show that paediatric patients
receiving dialysis were signiﬁcantly more underweight
for age and sex than those with renal transplants. The
overall median z-score was −0.2 in the transplanted
group and −1.1 in the dialysis group (p , 0.0001).
Centre level comparison for dialysis patients in par-
ticular should be avoided due to low numbers per
centre.
When taking Ht into account and examining BMI
rather than Wt alone, ﬁgures 9.8 and 9.9 show that
BMI z-scores were mostly within the upper half of the
normal range for transplant patients and spread through-
out the normal range in dialysis patients. Evelina was
excluded from ﬁgure 9.9 as stated above. The majority
of paediatric RRT patients had a BMI within the normal
range, as shown in ﬁgure 9.10.
Cardiovascular risk factor evaluation
Obesity
Figures 9.8 and 9.9 show that children with renal
transplants had a signiﬁcantly higher BMI for age and
sex than those receiving dialysis. The overall median
z-score was 1.0 in the transplanted group and 0.2 in the
dialysis group (p , 0.0001).
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Figure 9.10 demonstrates higher proportions of over-
weight and obese children in those with renal transplants
(43.6%) compared to those receiving dialysis (21.9%).
There was a higher proportion of underweight children
in the dialysis group (6.2%) compared to those with
renal transplants (0.7%).
Of those aged 16 to,18 years, 45.1% were overweight
or obese compared to 19.4% of those aged zero to under
ﬁve years, but there was no signiﬁcant difference by age
in the transplant patient group alone. There were no
statistically signiﬁcant differences between proportions
of those underweight, normal, overweight or obese in
terms of sex, ethnicity or donor source (deceased or
living).
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Hypertension
Figures 9.11 and 9.12 show paediatric patients receiv-
ing RRT were hypertensive compared to the healthy
population and those receiving dialysis had a signiﬁcantly
higher median SBP than those with renal transplants.
There was wide inter-centre variability in median SBP
z-score. The median SBP z-score was maintained at or
below the 90th percentile by all centres for transplant
patients and in nine centres for dialysis patients. The
overall median SBP z-score was 0.5 in the transplanted
group and 0.8 in the dialysis group (p , 0.0001). Of
those aged,18 years, 81.8% of children with a function-
ing kidney transplant and 63.0% of those receiving
dialysis had an SBP ,90th percentile in 2015 (no differ-
ence between HD and PD). No comments can be made at
centre level or for dialysis patient subgroups due to small
patient numbers. Table 9.6 shows that there were signiﬁ-
cant differences in the percentage below the 90th percen-
tile for SBP between different age groups, gender and
RRT modality. There was no signiﬁcant difference in
SBP between ethnicity, HD and PD or between living
and deceased donor transplants.
Prevalence of cardiovascular risk factors
Table 9.7 shows that the percentage of patients with no
CVRFs was 24.8%, one CVRF was 40.9%, two CVRFs was
27.3% and the percentage of those with all evaluated
CVRFs was 7.0%. This analysis is restricted to the 487
of 941 (51.8%) patients with complete data for all three
items. Thus, of the included prevalent paediatric RRT
population three quarters had one or more risk factors
Pe
rc
en
ta
ge
 o
f p
at
ie
nt
s
Transplant Dialysis
Treatment modality
0
20
40
60
80
100
Underweight
Normal
Overweight
Obese
Fig. 9.10. BMI categorisation in children ,18 years old by
modality on 31st December 2015
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for cardiovascular disease. Of those included in this
analysis, 151 (31.0%) had hypertension, 214 (43.9%)
were overweight/obese and 202 (41.5%) had hypercholes-
terolaemia. There were no statistically signiﬁcant differ-
ences in number of CVRFs according to age, gender,
ethnicity or modality.
Laboratory and clinical indices – quarterly data
Tables 9.8 and 9.10 display the median values and
interquartile ranges (IQRs) for quarterly laboratory
parameters for paediatric transplant and dialysis patients
in 2015 by centre, with table 9.9 showing age-speciﬁc
creatinine results. The total number of data points for
each parameter varied depending on completeness,
ranging from 2,384 data points for creatinine in transplant
patients to 645 data points for ferritin in dialysis patients.
For transplant patients, these results demonstrate
excellent average renal allograft function in the paediatric
population, with associated good anaemia control and
normal bone metabolism markers. For comparison, the
median eGFR for all transplant patients (based on annual
rather than quarterly data) was 61 ml/min/1.73 m2 and
fell with age (83 if aged ,ﬁve years; 65 if aged ﬁve to
,12 years; 60 if aged 12–,16 years; and 52 if aged 16–
,18 years). The overall median ferritin in transplant
patients was 66 mg/L (IQR 32–145) based on 40% com-
pleteness. Similarly, the overall median PTH in trans-
plant patients was 6.9 pmol/L (IQR 4.6–10.6) based on
59% completeness.
For dialysis patients, the average Hb and ferritin were
within the target range. For bone biochemistry, although
average calcium and phosphate were in range, there was
evidence of hyperparathyroidism with average PTH over
target at more than twice the upper limit of normal, with
variation between centres. Control of acidosis was also
within the desired range.
Laboratory and clinical indices – annual data
Haemoglobin and ferritin
The percentage of patients aged ,18 years on dialysis
achieving the Hb standard in 2015 was 72.9% for those on
HD and 74.5% for those on PD, compared to 92.8% for
those with a renal transplant. There was no pattern by
age and no comments could be made at centre level or
for dialysis patients due to small patient numbers. During
2013–2015, 72.9% of dialysis patients and 92.2% of
Table 9.6. Percentage of patients ,18 years old achieving the
standard for SBP on 31st December 2015
N
% below
90th percentile p-value
Total 820 78.3
Age group (years) 0.001
0–,5 94 70.2
5–,12 337 73.9
12–,16 250 86.4
16–,18 139 79.9
Gender 0.04
Male 518 80.7
Female 302 74.2
Ethnicity 0.6
Black 31 83.9
Other 65 75.4
South Asian 128 75.8
White 568 79.2
RRT modality ,0.0001
Dialysis 154 63.0
Transplant 666 81.8
Table 9.7. Frequency of number of CVRFs in prevalent RRT patients ,18 years old on 31st December 2015
Number of CV risk factors Hypertensive OW/Obese Hypercholesterolaemic N % Total %
0 No No No 121 24.8 24.8
1 Yes No No 45 9.2
No Yes No 84 17.2 40.9
No No Yes 70 14.4
2 Yes Yes No 35 7.2
Yes No Yes 37 7.6 27.3
No Yes Yes 61 12.5
3 Yes Yes Yes 34 7.0 7.0
N 151 214 202
Total % 31.0 43.9 41.5
CV – cardiovascular; OW – overweight
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Table 9.8. Median quarterly laboratory data by centre in prevalent transplant patients ,18 years old on 31st December 2015
Centre
Transplant patients
Creatinine
(mmol/L)
Haemoglobin
(g/L)
Calcium
(mmol/L)
Phosphate
(mmol/L)
Bicarbonate
(mmol/L)
Bham_P 70 120 2.46 1.31 25
Blfst_P 77 124 2.47 1.21 22
Brstl_P 76 127 2.43 1.24 23
Cardf_P 65 126 2.50 1.32 23
Glasg_P 79 120 2.45 1.26 22
L Eve_P 84 120 2.46 1.20 22
L GOSH_P 81 124 2.48 1.49 25
Leeds_P 86 115 2.41 1.30 24
Manch_P 88 119 2.48 1.26 22
Newc_P 79 124 2.42 1.21 22
Nottm_P 76 124 2.43 1.28 25
Soton_P 94 115 2.50 1.30 24
UK median 79 122 2.46 1.31 24
IQR (59–107) (111–131) (2.39–2.52) (1.15–1.49) (22–26)
IQR interquartile range
Table 9.9. Median quarterly creatinine by age group, centre and time since transplant in prevalent transplant patients ,18 years
old on 31st December 2015
Age (years)
0–,5 5–,12 12–,16 16–,18
Centre N
Creatinine
(mmol/L) N
Creatinine
(mmol/L) N
Creatinine
(mmol/L) N
Creatinine
(mmol/L)
Bham_P 12 44 123 62 128 78 29 105
Blfst_P 5 46 52 84 10 57 2
Brstl_P 3 149 86 65 34 86 23 100
Cardf_P 6 41 39 63 29 69 8 72
Glasg_P 5 38 61 60 49 87 41 104
L Eve_P 23 41 96 71 103 89 58 116
L GOSH_P 43 39 233 69 184 94 92 123
Leeds_P 20 46 82 67 89 95 46 102
Manch_P 13 46 109 64 53 97 35 114
Newc_P 4 54 23 47 31 80 30 93
Nottm_P 16 31 96 74 62 77 35 108
Soton_P 9 51 26 95 23 95 5 98
Total N and UK median 159 41 1,026 67 795 88 404 107
IQR (34–52) (53–87) (70–115) (88–135)
Time since transplantation (years)
3 months 54 40 95 55 49 82 38 103
1 year 62 42 137 66 90 81 50 109
2.5 years 42 43 335 60 158 88 78 92
5 years 1 353 73 211 79 96 105
≥7 years 0 106 79 287 100 142 119
IQR interquartile range
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transplant patients achieved the standard for Hb, which
has remained consistent since the 2003–2006 period.
The proportion of patients with a ferritin in range during
2013–2015 was 35.8% for dialysis patients and 13.4% for
transplant patients. It is not possible to draw conclusions
on ferritin data trends, because the data completeness for
transplant patients was only 42.1% in the 2003–2006
period, but had improved to 79.0% in the 2013–2015
period. A similar improvement was also seen for dialysis
ferritin data, increasing from 75.0% to 95.1% over the
same time periods.
At ﬁrst inspection, table 9.11 appears to show over
time an increasing use of erythropoietin stimulating
agents (ESAs) in transplant patients and a decrease in
use of ESAs in dialysis patients. However, the amount
of missing data increased from 2.1% in the 2003–2006
period to 16.0% in the most recent period for dialysis
patients, and by a similar margin for the transplant
patients.
Overall, ﬁgure 9.13 shows high usage of ESAs in
dialysis patients without a clear difference by Hb stan-
dard, noting erratic results from 2010 when there was a
reduction in data completeness. Usage of ESAs in trans-
plant patients remained low and reasonably stable with a
more discernible separation by Hb standard. Figure 9.14
further demonstrates wider variation for usage of intrave-
nous (IV) iron for dialysis patients by Hb standard, in
keeping with low completeness for past years, and low
usage of IV iron in transplant patients.
Calcium
The percentage of patients aged ,18 years on HD
(N = 108) achieving the calcium standard in 2015 was
75.9%, with 3.7% of patients being hypocalcaemic and
20.4% being hypercalcaemic. The percentage of patients
aged ,18 years on PD (N = 99) achieving the calcium
standard in 2015 was 69.7%, with 1.0% being hypocalcae-
mic and 29.3% being hypercalcaemic. Small cohort
numbers prevent commentary at centre level or by age
group.
Phosphate
The percentage of patients aged ,18 years on HD
(N = 108) achieving the phosphate standard in 2015
Table 9.10. Median quarterly laboratory data by centre in prevalent dialysis patients ,18 years old on 31st December 2015
Centre
Dialysis patients
Hb
(g/L)
Ferritin
(mg/L)
Calcium
(mmol/L)
Phosphate
(mmol/L)
PTH
(pmol/L)
Bicarbonate
(mmol/L)
Bham_P 111 283 2.61 1.71 10.3 27
Blfst_P 117 1272 2.56 1.57 17.2 26
Brstl_P 111 284 2.52 1.41 16.0 25
Cardf_P 128 224 2.61 1.50 52.2 25
Glasg_P 116 210 2.49 1.14 22.1 24
L Eve_P 104 382 2.51 1.40 24.6 24
L GOSH_P 128 337 2.64 2.01 17.0 30
Leeds_P 100 311 2.44 1.95 58.4 25
Manch_P 107 149 2.58 1.65 31.0 25
Newc_P 108 278 2.60 1.32 9.7 23
Nottm_P 103 238 2.54 1.64 16.3 27
Soton_P 85 150 2.50 1.50 6.6 25
UK median 111 278 2.55 1.62 21.0 26
IQR (99–124) (129–467) (2.46–2.65) (1.30–1.99) (8.5–47.6) (23–29)
Hb – haemoglobin; PTH – parathyroid hormone; IQR – interquartile range
Table 9.11. Proportion of paediatric RRT patients on ESA, by
Hb attainment, across time
Time period
Hb below standard
% on ESA
Hb above standard
% on ESA
Transplant patients
2003–2006 21.1 4.2
2007–2009 21.4 5.6
2010–2012 20.0 5.7
2013–2015 31.9 3.6
Dialysis patients
2003–2006 97.1 93.2
2007–2009 95.9 91.0
2010–2012 82.9 81.0
2013–2015 87.5 96.1
Hb – haemoglobin; ESA – erythropoietin stimulating agent
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was 48.2%, with 18.5% of patients being hypophos-
phataemic and 33.3% being hyperphosphataemic. The
percentage of patients aged ,18 years on PD (N = 99)
achieving the phosphate standard in 2015 was 51.5%,
with 8.1% of patients being hypophosphataemic and
40.4% being hyperphosphataemic. Small cohort
numbers prevent commentary at centre level or by age
group.
Parathyroid hormone
The percentage of patients aged,18 years with a renal
transplant (N = 633) achieving the PTH standard in
2015 was 80.6%, with 19.4% having hyperparathyroid-
ism. The percentage of patients aged ,18 years on HD
(N = 110) achieving the PTH standard in 2015 was
44.6%, with 55.4% having hyperparathyroidism. The
percentage of patients aged ,18 years on PD (N = 99)
achieving the PTH standard in 2015 was 32.3%, with
67.7% having hyperparathyroidism. Small cohort
numbers and low completeness from some centres for
transplant patients prevent commentary at centre level
or by age group.
Bicarbonate
The percentage of patients aged ,18 years with a
renal transplant (N = 714) achieving the bicarbonate
standard in 2015 was 87.0%, with 9.5% being below
and 3.5% being above the standard. The percentage of
patients aged ,18 years on HD (N = 105) achieving
the bicarbonate standard in 2015 was 74.3%, with
10.5% being below and 15.2% being above the standard.
The percentage of patients aged ,18 years on PD
(N = 98) achieving the bicarbonate standard in 2015
was 58.2%, with 6.1% being below and 35.7% being
above the standard. Small cohort numbers prevent com-
mentary at centre level or by age group.
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2015 in prevalent RRT patients ,18 years
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Discussion
This chapter provides information describing clinical
and laboratory parameters of paediatric RRT patients
in the UK. This enables comparison against national
standards and guidelines, assessment of quality of care
and benchmarking the performance of UK tertiary pae-
diatric nephrology centres. Data from 2015 and trends
over the last 13 years have been analysed. The results
and conclusions are a valuable resource for the paediatric
renal community and these data account for nearly 20%
of the European Paediatric Renal Registry data.
Quarterly data
Twelve centres provided quarterly data for analyses, an
increase of two centres from the previous year. The data
show excellent graft function for those with a transplant,
with a breakdown by centre, age and time following
kidney transplant, which may be of value for clinicians.
The reporting of eGFR using quarterly data is not
possible due to low completeness of Ht data, but eGFR
using annual data to add to the assessment of transplant
function is given. For dialysis patients, the data again
demonstrate good control of anaemia and acidosis, with
a median PTH of 21 pmol/L, varying widely between
centres.
The ongoing challenge is to continue to work with the
remaining centre to achieve quarterly returns and to
improve extracts to allow new data to be loaded into a
single UKRR database.
Highlights from the 2015 data
For core items there was very good completeness; ESA
and IV iron data were limited in transplant patients
perhaps because these patients tend not to be anaemic.
Cholesterol and growth hormone remained the most
limited variables in terms of completeness, but reporting
levels were above the threshold to be used in analyses.
Growth
As previously reported, dialysis patients had lower
median height z-scores than transplanted patients, but
only constitute between a ﬁfth and a quarter of the popu-
lation. After taking completeness and IQRs into account,
the median Ht z-scores were similar between centres for
transplant patients (differing by a SD) and more widely
spread for dialysis patients, which is not surprising
given the smaller numbers per unit.
Taking into account 13 years of data, the overall
median Ht z-score at RRT start for UK children was
−1.4 (again with a wide IQR), demonstrating the
impact of a chronic disease in childhood and suggesting
there are opportunities to improve growth at earlier
stages of CKD. The data show that once transplanted,
patients maintained their Ht over the following ﬁve
years, with those transplanted under the age of ﬁve
years showing an improvement in Ht z-score since the
start of RRT.
Use of growth hormone remains difﬁcult to interpret
due to a high proportion of missing data, notwithstand-
ing the fact that there are alternative interventions to
improve growth which the UKRR does not collect.
Further, adjustment for situations where use of growth
hormone is not recommended, such as in newly trans-
planted patients and in those demonstrating catch-up
growth was not possible. There are plans to look at
reasons why short children are not on growth hormone
therapy and to look at the effects of steroid avoidance
on growth in transplanted patients. A signiﬁcant percen-
tage of transplant patients were overweight or obese and
steroid use may also contribute to weight gain.
While the median Wt z-score for transplant patients
was near that of the healthy population, the dialysis
patients were underweight, again accepting a wide IQR.
As dialysis patients and transplant patients were both
shorter on average than their healthy peers, this meant
that transplant patients had a higher BMI than their
healthy peers, with dialysis patients having relatively
normal BMI. Improvements to the completeness of Ht
and Wt in the quarterly data should allow growth rates
to be evaluated in the future. These data will also allow
evaluation of excessive Wt gain following kidney trans-
plantation [9], identiﬁed as the most prevalent CVRF in
children receiving RRT.
Cardiovascular risk factor evaluation
The analysis of SBP across different centres in 2015
continued to show variability both between and within
centres. Statistically fewer younger patients, girls and
dialysis patients achieved the SBP standard.
The data continue to show that the majority of chil-
dren on RRT have CVRFs – accepting the low complete-
ness of cholesterol data – consistent with previous reports
of RRT and pre-dialysis CKD cohorts [10, 11]. Given the
good completeness of other data it is interesting to specu-
late on the reason for lack of measurement of cholesterol
in children and young people. Many clinicians are reluc-
tant to treat mild to moderate hypercholesterolaemia due
to lack of data on tolerability and efﬁcacy of treatment in
these populations.
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Being overweight was the most common CVRF,
suggesting that weight should be a speciﬁc target for
intervention for long-term cardiovascular health of
paediatric RRT patients. Whilst 80% of patients had a
blood pressure below the 90th centile, there was evidence
in paediatric CKD patients that suggests lower targets
may be appropriate [12].
Laboratory and clinical indices
Annual data regarding attainment of standards for
laboratory measures were similar to previous years for
Hb, ferritin, calcium, phosphate, PTH and bicarbonate.
There is a new NICE guideline on the treatment of
anaemia in CKD and centres may be switching the way
they monitor iron stores. The data collected were from
before the introduction of the new guideline, which
may in part explain the low ﬁgures for ferritin measure-
ment. The new guidance should be reﬂected in the 2016
data.
The proportion of dialysis patients achieving the
standards appears low. However, over-interpretation of
single measurements of variable completeness from a
small proportion of the cohort should be avoided. Once
all centres are reporting quarterly biochemistry data,
replacement of the assessment of achievements of stan-
dards on the quarterly median rather than the annual
result will be possible.
Future work
The goals of the paediatric UKRR remain the reporting
of quarterly data for all paediatric renal centres, improv-
ing data extracts and then combining the adult and
paediatric UKRR databases.
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